NXC-201
Relapsed/Refractory AL Amyloidosis
Key Facts
About Nexcella
Nexcella is a U.S.-based biotech advancing CAR-T cell therapy NXC-201 for the rare disease AL Amyloidosis, an area with significant unmet need and no FDA-approved CAR-T options. The company has generated promising early clinical data showing a 92% overall response rate and recently secured an $8 million grant from CIRM to support its ongoing NEXICART-2 U.S. trial. As a subsidiary of publicly-traded Immix Biopharma (IMMX), Nexcella leverages its parent's resources and expertise while aiming to address neurotoxicity challenges in CAR-T to improve accessibility for patients with immune-mediated diseases.
View full company profileAbout Immix Biopharma
Immix Biopharma's mission is to harness the immune system through innovative cell therapies to deliver widely accessible cures. The company's core achievement is the development of its N-GENIUS platform, which has produced NXC-201, a CAR-T therapy demonstrating a transformative safety profile with 0% neurotoxicity in AL amyloidosis and high response rates. Its strategy is to overcome the primary barrier to CAR-T adoption—neurotoxicity—to expand into new disease indications and the 95% of U.S. medical centers currently unable to dose existing CAR-T therapies, starting with a planned BLA submission in AL amyloidosis.
View full company profileAbout Immix Biopharma
Immix Biopharma's mission is to harness the immune system through innovative cell therapies to deliver widely accessible cures. The company's core achievement is the development of its N-GENIUS platform, which has produced NXC-201, a CAR-T therapy demonstrating a transformative safety profile with 0% neurotoxicity in AL amyloidosis and high response rates. Its strategy is to overcome the primary barrier to CAR-T adoption—neurotoxicity—to expand into new disease indications and the 95% of U.S. medical centers currently unable to dose existing CAR-T therapies, starting with a planned BLA submission in AL amyloidosis.
View full company profileAbout Immix Biopharma
Immix Biopharma's mission is to harness the immune system through innovative cell therapies to deliver widely accessible cures. The company's core achievement is the development of its N-GENIUS platform, which has produced NXC-201, a CAR-T therapy demonstrating a transformative safety profile with 0% neurotoxicity in AL amyloidosis and high response rates. Its strategy is to overcome the primary barrier to CAR-T adoption—neurotoxicity—to expand into new disease indications and the 95% of U.S. medical centers currently unable to dose existing CAR-T therapies, starting with a planned BLA submission in AL amyloidosis.
View full company profile